Cytek Biosciences, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

MiMedx Group, Inc.

SI-BONE, Inc.

Paragon 28, Inc.

Varex Imaging Corp.

Treace Medical Concepts, Inc.

Avanos Medical, Inc.

Embecta Corp.

OrthoPediatrics Corp.

The Beauty Health Co.

Cytek Biosciences, Inc.

Quanterix Corp.

Why is Cytek Biosciences, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of -5.71% over the last 5 years

INTEREST(HY) At USD 0.91 MM has Grown at 258.89%
PRE-TAX PROFIT(Q) At USD -7.77 MM has Fallen at -5,048.41%
NET PROFIT(Q) At USD -5.48 MM has Fallen at -682.15%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -1.67%, its profits have fallen by -117.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -1.67% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Cytek Biosciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Cytek Biosciences, Inc.

-1.67%

-0.47

66.92%

S&P 500

18.81%

0.98

19.26%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-5.71%

EBIT Growth (5y)

4.55%

EBIT to Interest (avg)

-4.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.65

Sales to Capital Employed (avg)

0.47

Tax Ratio

41.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

75.52%

ROCE (avg)

12.81%

ROE (avg)

0.28%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.40

EV to EBIT

-8.45

EV to EBITDA

-12.74

EV to Capital Employed

2.10

EV to Sales

1.48

PEG Ratio

Dividend Yield

ROCE (Latest)

-24.84%

ROE (Latest)

-5.83%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -11.06 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.86 times

-25What is not working for the Company

INTEREST(HY)

At USD 0.91 MM has Grown at 258.89%

PRE-TAX PROFIT(Q)

At USD -7.77 MM has Fallen at -5,048.41%

NET PROFIT(Q)

At USD -5.48 MM has Fallen at -682.15%

OPERATING CASH FLOW(Y)

Lowest at USD -1.91 MM

DEBT-EQUITY RATIO (HY)

Highest at -59.85 %

RAW MATERIAL COST(Y)

Grown by 6.56% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.44 times

Here's what is working for Cytek Biosciences, Inc.

Inventory Turnover Ratio

Highest at 1.86 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Depreciation

Highest at USD 3.06 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Cytek Biosciences, Inc.

Interest

At USD 0.91 MM has Grown at 258.89%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -7.77 MM has Fallen at -5,048.41%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -5.48 MM has Fallen at -682.15%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -59.85 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Cash Flow

Lowest at USD -1.91 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debtors Turnover Ratio

Lowest at 3.44 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 6.56% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales